PDMR Dealing

LONDON, March 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 22, 2019, Mr. Piers Morgan, CFO of the Company, purchased 20,132 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 64 pence per Ordinary Share and a total purchase price of £12,884.48  Following the acquisition, Mr. Morgan will have an interest in the Company of 113,207 Ordinary Shares, representing 0.11% of the Company’s issued share capital.

The purchase by Mr. Morgan brings the total purchases made by him this month to £32,884.46 and follows the purchases made by the Company’s Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated



Piers Morgan
2 Reason for the notification

Position/status Chief Financial Officer

Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name Verona Pharma plc

LEI 213800EVI6O6J3TIAL06


4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

Identification code
Ordinary Shares of 5 pence each



Nature of the transaction
Piers Morgan purchased 20,132 Ordinary Shares


Price(s) and volume(s)

Price(s) Volume(s)
64 pence per Ordinary Share 20,132 Ordinary Shares


Aggregated information

-  Aggregated volume

-  Price


Date of the transaction 22 March 2019

Place of the transaction London Stock Exchange, AIM


For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  



Source: Verona Pharma plc